Compare Novartis with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs SREELEATHERS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS SREELEATHERS NOVARTIS/
SREELEATHERS
 
P/E (TTM) x 86.7 22.8 380.5% View Chart
P/BV x 2.7 1.2 226.4% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 NOVARTIS   SREELEATHERS
EQUITY SHARE DATA
    NOVARTIS
Mar-21
SREELEATHERS
Mar-21
NOVARTIS/
SREELEATHERS
5-Yr Chart
Click to enlarge
High Rs770170 453.2%   
Low Rs501110 455.5%   
Sales per share (Unadj.) Rs154.535.9 429.6%  
Earnings per share (Unadj.) Rs8.54.8 176.0%  
Cash flow per share (Unadj.) Rs13.45.3 250.7%  
Dividends per share (Unadj.) Rs10.000-  
Avg Dividend yield %1.60-  
Book value per share (Unadj.) Rs289.2135.4 213.7%  
Shares outstanding (eoy) m24.6923.19 106.5%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x4.13.9 105.7%   
Avg P/E ratio x75.129.1 257.9%  
P/CF ratio (eoy) x47.526.2 181.1%  
Price / Book Value ratio x2.21.0 212.5%  
Dividend payout %118.10-   
Avg Mkt Cap Rs m15,6913,246 483.4%   
No. of employees `000NANA-   
Total wages/salary Rs m1,08532 3,344.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m3,814834 457.4%  
Other income Rs m3324 7,511.3%   
Total revenues Rs m4,146838 494.6%   
Gross profit Rs m267163 163.8%  
Depreciation Rs m12212 983.8%   
Interest Rs m773 2,213.3%   
Profit before tax Rs m400151 264.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m19140 479.5%   
Profit after tax Rs m209112 187.4%  
Gross profit margin %7.019.5 35.8%  
Effective tax rate %47.826.4 181.3%   
Net profit margin %5.513.4 41.0%  
BALANCE SHEET DATA
Current assets Rs m9,224184 5,010.6%   
Current liabilities Rs m3,57390 3,950.7%   
Net working cap to sales %148.211.2 1,319.2%  
Current ratio x2.62.0 126.8%  
Inventory Days Days176699 25.2%  
Debtors Days Days371,727,709 0.0%  
Net fixed assets Rs m2,4803,117 79.5%   
Share capital Rs m123232 53.2%   
"Free" reserves Rs m7,0182,907 241.4%   
Net worth Rs m7,1413,139 227.5%   
Long term debt Rs m00-   
Total assets Rs m11,7033,302 354.5%  
Interest coverage x6.244.6 13.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.30.3 129.0%   
Return on assets %2.43.5 70.1%  
Return on equity %2.93.6 82.4%  
Return on capital %6.74.9 135.4%  
Exports to sales %9.30-   
Imports to sales %00-   
Exports (fob) Rs m354NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3540-   
Fx outflow Rs m9740-   
Net fx Rs m-6210-   
CASH FLOW
From Operations Rs m-692109 -634.8%  
From Investments Rs m952246 387.5%  
From Financial Activity Rs m-368-332 110.8%  
Net Cashflow Rs m-10922 -484.6%  

Share Holding

Indian Promoters % 0.0 72.3 -  
Foreign collaborators % 70.7 0.0 -  
Indian inst/Mut Fund % 0.8 5.3 15.4%  
FIIs % 0.0 5.0 0.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.3 27.7 105.8%  
Shareholders   45,141 7,724 584.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   DHOOT IND FIN.  BIJOY HANS  TRIJAL IND.  AMRAWORLD AGRICO  BRAND CONCEPTS  



Today's Market

India's Fiscal Deficit, Anand Rathi Wealth IPO, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a negative note yesterday. Benchmark indices edged lower as global cues turned bearish after US pharma.

Related Views on News

SREELEATHERS 2020-21 Annual Report Analysis (Annual Result Update)

Nov 18, 2021 | Updated on Nov 18, 2021

Here's an analysis of the annual report of SREELEATHERS for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of SREELEATHERS. Also includes updates on the valuation of SREELEATHERS.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market(Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing.(Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Nov 30, 2021 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - AGRIMONY COMM. COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS